Privacy settings

Utilizziamo cookies tecnici, necessari per il corretto funzionamento del sito, cookies statistici e cookies di marketing (inclusi cookies di terze parti), al fine di mostrarti offerte e pubblicità basate sui tuoi gusti e preferenze. Per maggiori informazioni puoi consultare la nostra Privacy Policy. I cookies statistici e i cookies di marketing (inclusi cookies di terze parti) sono utilizzati esclusivamente con il tuo consenso. Cliccando “Seleziona tutto e acconsenti” consenti il trattamento dei cookies statistici e di marketing (inclusi cookies di terze parti).

Per personalizzare le tue impostazioni privacy, seleziona le tue preferenze tra le caselle qui sotto e clicca “Applica la selezione”. Ti ricordiamo per puoi modificare le tue impostazioni privacy in qualsiasi momento e disattivare i cookies, seguendo le istruzioni riportate nella Privacy Policy.

Show preferences Select all and accept
IMA is loading

3rd International Symposium on Continuous Manufacturing of Pharmaceuticals • London (UK), 03-04 October 2018

Post published on 25/09/2018

IMA Active at the 3rd International Symposium on Continuous Manufacturing of Pharmaceuticals

IMA Active is pleased to take part in the 3rd International Symposium on Continuous Manufacturing of Pharmaceuticals, which will be held at the Grange St. Paul’s Hotel, in London (UK), on October 03-04, 2018.

The symposium will bring together pharmaceutical company end users, suppliers, regulators and academics to look at accelerating adoption of Continuous Manufacturing for both small molecules and biologic products and how research groups, globally, might collaborate more to help drive this. An enormous opportunity to guide the way in which new technologies and new approaches in the pharmaceutical industry can transform quality, cost and service for the benefit of the patient.

Nicola Gandolfi, IMA Active Technical Manager for Granulation and Coating, will held the presentation “Prexima and Croma, integrated technologies for Continuous Manufacturing”.

Objectives

  • Continue and accelerate implementation based on progress made since 2014 Symposium
  • Provide practical guidance based on real case studies
  • Identify remaining gaps and develop appropriate solutions and next steps
  • Continue to engage key stakeholders (academic, industry and regulators)
  • 2014 White papers and 2016 symposium output can lay the foundation of a future ICH guideline

Themes

  • Small Molecules
  • Bioprocessing
  • Vendor Perspective
  • Supply Chain Implications
  • Regulatory

Get in touch

For any further information